BNTC

Benitec Biopharma Inc

9.04

Oct 20 • 3:59 PM ET +0.68 (8.13%)

9.04

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: DYN SLDB RGNX WVE SRPT TRDA PEPG CAPR QURE TSHA

| Held by: PINK VTI IWM VXF IWN VTWO IWC GNOM AVSC VTWV

Scroll to Statements

Index	RUT
Market Cap	315.32M
Enterprise Value	135.99M
Income	-45.55M
Sales	0.00M
Book/sh	5.14
Cash/sh	5.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	24
IPO	Jun 23, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.76
P/C	1.75
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	34.00
Current Ratio	34.00
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.09
EPS next Y	-1.43
EPS next Q	-0.27
EPS this Y	-22.89%
EPS next Y	-19.02%
EPS next 5Y	-12.09%
EPS past 3/5Y	58.92% 55.32%
Sales past 3/5Y	- -
EPS Y/Y TTM	14.04%
Sales Y/Y TTM	-
EPS Q/Q	-74.01%
Sales Q/Q	-
Earnings	Sep 14 AMC
EPS/Sales Surpr.	-1.21% -

Insider Own	2.51%
Insider Trans	0.00%
Inst Own	99.27%
Inst Trans	2.22%
ROA	-32.28%
ROE	-33.21%
ROIC	-25.69%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.76%
SMA50	-18.29%
SMA200	-22.56%
Trades

Shs Outstand	34.42M
Shs Float	34.01M
Short Float	6.00%
Short Ratio	12.53
Short Interest	2.04M
52W High	16.76 -46.06%
52W Low	8.00 13.00%
Volatility	7.88% 8.28%
ATR (14)	0.69
RSI (14)	42.95
Beta	0.25
Rel Volume	2.14
Avg Volume	162.79K
Volume	347,606

Perf Week	4.75%
Perf Month	-16.91%
Perf Quarter	-20.98%
Perf Half Y	-31.41%
Perf YTD	-32.89%
Perf Year	-44.30%
Perf 3Y	186.08%
Perf 5Y	-85.10%
Perf 10Y	-97.46%
Recom	1.14
Target Price	24.33
Prev Close	8.36
Price	9.04
Change %	8.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-26	Initiated	Wedbush	Outperform	$16
Jun-10-26	Downgrade	Guggenheim	Buy → Neutral
May-12-26	Initiated	Evercore ISI	Outperform	$25
Jul-07-25	Initiated	TD Cowen	Buy
Dec-16-24	Initiated	H.C. Wainwright	Buy	$28
Dec-13-24	Initiated	Robert W. Baird	Outperform	$30
Oct-16-24	Initiated	Oppenheimer	Outperform	$35
Sep-12-24	Initiated	Guggenheim	Buy	$17
Jul-22-24	Initiated	Leerink Partners	Outperform	$13
Jun-13-24	Initiated	Piper Sandler	Overweight	$30
Oct-05-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Apr-20-20	Initiated	Ladenburg Thalmann	Buy	$14
Feb-26-16	Downgrade	Maxim Group	Buy → Hold
Dec-31-15	Reiterated	Maxim Group	Buy	$23 → $14
Sep-16-15	Reiterated	Maxim Group	Buy	$4 → $23

Show Previous Ratings

Oct-05-26 08:00AM	Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study (GlobeNewswire)
Sep-14-26 04:00PM	Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update (GlobeNewswire) -8.53%
May-14-26 08:00AM	Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
Apr-28-26 07:00AM	Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-27-26 07:05AM	PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors (Business Wire)
07:00AM	Loading…
Mar-10-26 07:00AM	Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) (GlobeNewswire)
Mar-09-26 07:00AM	Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire) +10.67%
Feb-23-26 07:00AM	Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-12-26 08:30AM	Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
Jan-11-26 08:00AM	Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response (GlobeNewswire)
Dec-24-25 09:55AM	Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect? (Zacks)
Dec-05-25 09:55AM	Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know (Zacks)
Dec-03-25 09:35AM	Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) (Zacks) +7.98%
Nov-18-25 06:16AM	Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment (Insider Monkey)
Nov-14-25 05:00PM	Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
09:45AM	Loading…
Nov-12-25 09:45AM	Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others (24/7 Wall St.)
Nov-06-25 12:19AM	Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering (GlobeNewswire) -23.95%
Nov-05-25 04:43PM	Benitec Biopharma Inc. Announces Proposed Public Offering (GlobeNewswire)
Nov-03-25 07:10AM	Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 (GlobeNewswire)
07:00AM	Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors (GlobeNewswire)
Nov-02-25 07:00PM	Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy (GlobeNewswire)
Sep-22-25 04:05PM	Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update (GlobeNewswire)
Jul-09-25 08:00AM	Benitec Biopharma Provides Operational Updates (GlobeNewswire) +9.67%
Jun-20-25 09:40AM	Is Cintas (CTAS) Stock Outpacing Its Business Services Peers This Year? (Zacks)
09:40AM	Is Ardagh Metal Packaging (AMBP) Stock Outpacing Its Industrial Products Peers This Year? (Zacks)
09:40AM	Are Basic Materials Stocks Lagging Harmony Gold (HMY) This Year? (Zacks)
09:40AM	Is Root (ROOT) Stock Outpacing Its Finance Peers This Year? (Zacks)
09:40AM	Are Utilities Stocks Lagging CenterPoint Energy (CNP) This Year? (Zacks)
09:40AM	Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:40AM	Has Karooooo (KARO) Outpaced Other Computer and Technology Stocks This Year? (Zacks)
09:40AM	Loading…
09:40AM	Are Consumer Staples Stocks Lagging Ahold (ADRNY) This Year? (Zacks)
09:40AM	Are Auto-Tires-Trucks Stocks Lagging Aisin Seiki (ASEKY) This Year? (Zacks)
Jun-16-25 08:50AM	Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jun-05-25 09:55AM	Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? (Zacks)
Jun-04-25 09:40AM	Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-25 08:50AM	Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why (Zacks)
May-20-25 09:55AM	Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet (Zacks)
May-19-25 09:40AM	Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year? (Zacks)
May-14-25 07:00AM	Benitec Biopharma Releases Third Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 08:50AM	Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-02-25 09:40AM	Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
Apr-25-25 09:55AM	Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade (Zacks)
Apr-23-25 12:00PM	What Makes Benitec Biopharma (BNTC) a New Buy Stock (Zacks)
Apr-16-25 09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Apr-15-25 11:51PM	Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-25-25 08:00AM	Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering (GlobeNewswire)
Mar-19-25 07:00AM	Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-26-25 07:00AM	Benitec Biopharma to Participate in Upcoming Conferences in March (GlobeNewswire)
Feb-20-25 09:55AM	Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know (Zacks)
Feb-14-25 08:10AM	Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire) +15.98%
08:00AM	Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Jan-27-25 08:00AM	Benitec Biopharma to Participate in Upcoming Conferences in January and February (GlobeNewswire)
Jan-13-25 09:49AM	Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock (Zacks) -5.55%
Dec-17-24 06:25AM	Benitec Biopharma initiated with a Buy at H.C. Wainwright (TipRanks)
Dec-09-24 09:55AM	Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? (Zacks) +8.46%
08:50AM	Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-26-24 07:00AM	Benitec Biopharma to Participate in Upcoming Investor Conferences in December (GlobeNewswire)
Nov-14-24 04:30PM	Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-04-24 08:00AM	Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference (GlobeNewswire)
Oct-25-24 05:01PM	Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc (GuruFocus.com)
Oct-14-24 06:00AM	Benitec Biopharma Announces Updated Investor Webcast Information (GlobeNewswire) -6.45%
Oct-12-24 06:30AM	Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-30-24 09:03PM	Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc (GuruFocus.com) +19.42%
Sep-26-24 04:30PM	Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update (GlobeNewswire) +5.01%
Sep-18-24 08:00AM	Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-17-24 08:00AM	Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar (GlobeNewswire)
Jul-15-24 06:00AM	Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study (GlobeNewswire) +7.71%
Jul-01-24 07:00AM	Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors (GlobeNewswire)
May-13-24 02:53PM	BNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024 (InvestorPlace) -12.22%
08:15AM	Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
May-01-24 08:00AM	Benitec Biopharma to Participate in the Citizens JMP Life Science Conference (GlobeNewswire) -6.51%
Apr-18-24 07:30AM	Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study (GlobeNewswire) +42.08%
07:00AM	Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million (GlobeNewswire)
Apr-09-24 08:00AM	Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024 (GlobeNewswire)
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Feb-13-24 08:00AM	Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-30-23 07:00AM	Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (GlobeNewswire)
Nov-17-23 08:00AM	Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-23 08:00AM	Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Sep-21-23 08:00AM	Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-21-23 09:02PM	Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc (GuruFocus.com)
Aug-18-23 09:02PM	JANUS HENDERSON GROUP PLC Acquires New Stake in Benitec Biopharma Inc (GuruFocus.com)
Aug-11-23 01:00PM	Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering (GlobeNewswire)
Aug-08-23 10:30PM	Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering (GlobeNewswire) +65.80%
Jul-25-23 01:00PM	Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023 (GlobeNewswire)
Jun-26-23 08:00AM	Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (GlobeNewswire) +80.90%
May-15-23 08:00AM	Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
May-08-23 08:05AM	Benitec Biopharma to Present at the OPMD International Conference (GlobeNewswire)
08:00AM	Benitec Biopharma to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Feb-13-23 08:00AM	Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Jan-23-23 09:48AM	Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program (GlobeNewswire) +9.08%
Nov-10-22 08:00AM	Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire) +5.79%
Sep-16-22 08:42AM	Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering (GlobeNewswire) -15.43%
Sep-12-22 10:06PM	Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering (GlobeNewswire) -6.63% -28.34%
Sep-02-22 08:00AM	Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update (GlobeNewswire)
Jul-15-22 06:52AM	Having purchased US$827k worth of Benitec Biopharma Inc. (NASDAQ:BNTC) stock, the recent 11% pullback is not what insiders may have expected (Simply Wall St.) +7.00%
May-16-22 08:15AM	Benitec Biopharma Releases Q3 2022 Financial Results (GlobeNewswire) -8.79%
Feb-14-22 08:00AM	Benitec Biopharma Discloses Q2 2022 Financial Results (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 29 '25	Buy	13.44	77,387	1,040,081	9,700,195	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 23 '25	Buy	12.85	50,000	642,500	9,620,075	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 26 '25	Buy	13.10	16,836	220,552	9,634,395	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 22 '25	Buy	12.08	19,542	236,067	9,577,475	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 19 '25	Buy	11.48	16,384	188,088	9,560,825	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 18 '25	Buy	11.24	10,215	114,817	9,546,875	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Nov 07 '25	Buy	13.50	1,481,481	19,999,994	9,538,175	Nov 10 09:51 PM

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. Its proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

Ph.D.Dr. Jerel A. Banks M.D.

C.A.Ms. Megan Joan Boston B.Com.

Chief Operating OfficerMs. Sophie Mukadam

Head of Discovery & Founding ScientistDr. Michael Graham

Senior Vice President of ManufacturingDr. Claudia Kloth Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BNTC

Benitec Biopharma Inc

Upgrade your Finviz experience